TNDM:NSD-Tandem Diabetes Care Inc. (USD)

EQUITY | Medical Devices | NASDAQ Global Market

Last Closing

USD 21.48

Change

+0.76 (+3.67)%

Market Cap

USD 0.07B

Volume

1.45M

Analyst Target

USD 120.13
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Tandem Diabetes Care Inc is a medical device company engaged in the designing, development and commercialization of products for people with insulin-dependent diabetes. The Company's flagship product is the t:slim Insulin Delivery System.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-27 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-2.12 (-2.44%)

USD 33.20B
PODD Insulet Corporation

+0.30 (+0.09%)

USD 21.86B
MASI Masimo Corporation

+1.96 (+1.26%)

USD 8.49B
BRKR Bruker Corporation

+0.29 (+0.78%)

USD 5.69B
TMDX TransMedics Group Inc

-0.93 (-0.72%)

USD 4.11B
IRTC iRhythm Technologies Inc

+0.87 (+0.62%)

USD 3.38B
PRCT Procept Biorobotics Corp

-2.93 (-5.00%)

USD 3.17B
LIVN LivaNova PLC

+0.38 (+0.89%)

USD 2.40B
SSII SS Innovations International I..

+0.95 (+18.70%)

USD 2.20B
NVCR Novocure Ltd

+0.03 (+0.15%)

USD 1.94B

ETFs Containing TNDM

EDOC:SW 4.04 % 0.00 %

N/A

N/A
XHE SPDR® S&P Health Care Eq.. 2.17 % 0.35 %

+0.03 (+0%)

USD 0.17B
SLIM 0.00 % 0.50 %

N/A

N/A
SSLY 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -40.37% 32% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -40.37% 32% F 16% F
Trailing 12 Months  
Capital Gain -59.40% 23% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.40% 23% F 15% F
Trailing 5 Years  
Capital Gain -74.19% 46% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -74.19% 46% F 17% F
Average Annual (5 Year Horizon)  
Capital Gain 41.46% 81% B- 88% B+
Dividend Return 41.46% 81% B- 87% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 314.66% 16% F 8% B-
Risk Adjusted Return 13.18% 67% D+ 49% F
Market Capitalization 0.07B 87% B+ 75% C

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 495.13 4% 2%
Price/Book Ratio 4.57 34% 25%
Price / Cash Flow Ratio 49.62 7% 5%
Price/Free Cash Flow Ratio -10.72 85% 92%
Management Effectiveness  
Return on Equity -33.30% 66% 37%
Return on Invested Capital -17.06% 60% 34%
Return on Assets -6.45% 72% 39%
Debt to Equity Ratio 117.17% 30% 18%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector